Doxepin: Phase II data

Data from a double-blind, placebo-controlled, 4-way crossover, U.S. Phase II trial in 71 elderly patients showed that low-doses of 1, 3 and 6 mg doxepin met the primary endpoint of WTDS compared to pl...